483
Bristol-Myers Squibb CompanyFDA 483 - Bristol-Myers Squibb Company - December 06, 2024
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Record Details
Bristol-Myers Squibb Company, located in Madison, NJ, received a Form 483 for deficiencies in its Risk Evaluation and Mitigation Strategy (REMS) for THALOMID. The inspection revealed failures in adhering to the REMS audit schedule, monitoring patient pregnancy tests, and providing complete training materials to healthcare providers and pharmacies. These issues indicate a lack of robust controls in ensuring the safe use and distribution of the drug.
Open in Dashboard
ID · 97218ac0-74e3-4a85-83a2-081a9e0504fb